TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16202499
Drug: G-Bond (GB)
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (GB) with strong air-blowing (s)
Study: 10709161
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg (6 days single-dose and 2 days multiple-dose 10 mg q 4 hours for three doses, total daily dose of 30 mg on Days 7 and 8)
Study: 17073859
Drug: Single 30-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group, n=32)
Study: 17073859
Drug: Two separate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group, n=32)
Study: 17073859
Drug: Single 30-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group, n=32)
Study: 17073859
Drug: Single 30-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group)
Study: 15204149
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg per day of cyclosporine A (CsA) for 4 weeks
Study: 24515510
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of daily oral vitamin D3
Study: 24515510
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of daily oral vitamin D3
Study: 12883103
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy
Study: 20870000
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy
Study: 3081918
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg b.d.)
Study: 1810260
Drug: Ranitidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine and Theophylline (500 mg b.d.)
Study: 1810260
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Theophylline (500 mg b.d.)
Study: 6194037
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid by intestinal infusion for 2 hours while 10% Intralipid was infused intravenously during the second hour
Study: 15118280
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet agent or anticoagulant
Study: 9382660
Drug: EDTU care
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTU care (inhaled adrenergic agonists and steroids for up to 9 hours)
Study: 8104738
Drug: Nonselective beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective beta-blocker propranolol
Study: 8104738
Drug: Beta 1-selective
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 1-selective blocker metoprolol
Study: 18326960
Drug: Irbesartan (ARB)
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan (ARB) monotherapy at maximal dose
Study: 17132971
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg b.i.d.; n=203)
Study: 10699097
Drug: Early low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early low-dose indomethacin therapy
Study: 8450099
Drug: Immediate cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cognitive-behavior therapy (8-week group intervention)
Study: 8450099
Drug: Delayed cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cognitive-behavior therapy (8-week group intervention)
Study: 31672172
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (G, n=7)
Study: 21361732
Drug: O2A1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2A1 group (omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day)
Study: 21361732
Drug: O1A1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: O1A1 group (omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day)
Study: 21361732
Drug: Subsequent antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent antibiotic susceptibility‐driven proton pump inhibitor‐based triple therapy
Study: 12660485
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with implant (DS)
Study: 10981569
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg every 8 h
Study: 23777506
Drug: Miglitol 50
Normalized name: miglitol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 50 mg with each meal for 1 week
Study: 23777506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-diabetic agent for 1 week)
Study: 20620320
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (ceftriaxone and metronidazole, once daily for a minimum of 5 days)
Study: 20620320
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (amoxicillin/clavulanate, after tolerating a regular diet for 7 days)
Study: 16644316
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (81 mg)
Study: 16644316
Drug: Standard aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aspirin (81 mg)
Study: 10780937
Drug: Enteral Glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral Glutamine (0.5 g x kg(‐1) x day(‐1) for 2 days)
Study: 1652611
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prochlorperazine 10 mg every 6 hr
Study: 31818266
Drug: Routine dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dialysis initiation at eGFR 7 ml/min/1.73 m2
Study: 31818266
Drug: Deferred dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred dialysis initiation at eGFR 5 ml/min/1.73 m2 or less
Study: 26545541
Drug: Stretching program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching program performed twice a week for eight weeks
Study: 21526923
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered monthly
Study: 21526923
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered as needed
Study: 21526923
Drug: Ranibizumab administered
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab administered as needed
Study: 19525191
Drug: Short-course rituximab/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course rituximab/chemotherapy
Study: 15673996
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of standardized turmeric extract taken daily for 8 weeks
Study: 11350464
Drug: Saline 1
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1 mL
Study: 7008244
Drug: PT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT group (anticoagulant dosage according to PT)
Study: 9617377
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonist plus dexamethasone
Study: 26669548
Drug: Roughened surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roughened surface implants
Study: 22739141
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH; 150 U/kg)
Study: 22739141
Drug: All heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All heparin treatments
Study: 8847874
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg/day)
Study: 14644895
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (HT)
Study: 8510086
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25-100 mg four times daily
Study: 27787895
Drug: Ultrasound-guided, single-injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided, single-injection, femoral nerve block followed by continuous fascia iliaca block
Study: 18416885
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate (CH) 10 g in 25 mL liquid formulation
Study: 18416885
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 mL liquid containing xanthan)
Study: 15665549
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times a day for 2 months
Study: 11839142
Drug: NRTI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI + protease inhibitor
Study: 10084409
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) 4.5 g i.v. every six hours (n = 75)
Study: 10084409
Drug: Imipenem/cilastatin (I/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (I/C) 500 mg i.v. every six hours (n = 75)
Study: 7781402
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and alternating chemotherapy strategies
Study: 6650444
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment of 400 mg cholesterol per day with exercise (MX)
Study: 6650444
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment of 1400 mg cholesterol per day with exercise (HX)
Study: 6650444
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment of 1400 mg cholesterol per day without exercise (HS)
Study: 28787388
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (2 daily oral doses of 2 × 10 CFUs for 5 days)
Study: 28787388
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 daily doses for 5 days)
Study: 24214140
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine (0.2 %) twice daily for 6 months
Study: 11772828
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block with 10 mL of 0.5% bupivacaine
Study: 11772828
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block with 10 mL of 0.9% saline (placebo)
Study: 7807622
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management using trained community health workers with thrice weekly home visits and treatment based on WHO recommendations
Study: 2561409
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 x 4 mg daily by inhalation)
Study: 31813384
Drug: High-oleic peanuts
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-oleic peanuts (56 g) within a hypoenergetic diet
Study: 31813384
Drug: Conventional peanuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional peanuts (56 g) within a hypoenergetic diet
Study: 18068281
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (azacytidine and decitabine)
Study: 17302078
Drug: Sevoflurane administered
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administered with tidal volume breathing (n=15)
Study: 17302078
Drug: Sevoflurane administered
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administered with vital capacity breaths (n=15)
Study: 9366624
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos)
Study: 9366624
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of Hormone Use interview (HHU) at the 3-year follow-up (HHU3yrs)
Study: 8322143
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate
Study: 30652487
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no amendments)
Study: 22669332
Drug: Ral 60
Normalized name: SYRINGE,ORAL 60ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ral 60 mg
Study: 22669332
Drug: Ral 30
Normalized name: Aloral 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ral 30 mg
Study: 22669332
Drug: n-3FA (Lovaza)
Normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3FA (Lovaza) 4 g
Study: 22669332
Drug: Lovaza 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza 4 g + Ral 30 mg
Study: 20055694
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate)
Study: 20055694
Drug: Calcipotriol (Cp)
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (Cp) monotherapy
Study: 20055694
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate (BD) monotherapy
Study: 18678843
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tolterodine + behavioral training)
Study: 18678843
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (tolterodine)
Study: 12855088
Drug: NTC (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTC (No Treatment Condition, just an interview)
Study: 10476617
Drug: Ozagrel Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ozagrel (DB12017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozagrel Hydrochloride (400 mg/day, orally)
Study: 8724617
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of oral misoprostol every 3 hours up to 5 doses
Study: 1680266
Drug: Ketobemidone (Ketogan)
Normalized name: chlorhexidine
DrugBank: Ketobemidone (DB06738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketobemidone (Ketogan) 1-1.5 ml
Study: 24043299
Drug: On-treatment CRP
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment CRP levels
Study: 15140341
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 7 days
Study: 1959402
Drug: Albuterol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (5 mg)
Study: 3296867
Drug: Metaproterenol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (15 mg)
Study: 31402563
Drug: Lateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral injection points performed first
Study: 31402563
Drug: Medial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial injection points performed first
Study: 17070267
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) solution
Study: 15342616
Drug: 8 patches
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 patches
Study: 15342616
Drug: 2 patches
Normalized name: Qutenza 8% Topical Patch Kit (2 Patches)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 patches
Study: 15342616
Drug: 4 and
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 and 8 patches
Study: 1768820
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg/kg)
Study: 9540175
Drug: RCT +
Normalized name: Recombinant tissue plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT + A (amifostine 500 mg prior to carboplatin)
Study: 6351333
Drug: Atropine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.6 mg)
Study: 346541
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medications)
Study: 9186381
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg/day)
Study: 3549601
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg/day)
Study: 8280822
Drug: Ranitidine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine continuous i.v. infusion (6.25 mg/h)
Study: 26808865
Drug: Raw milk
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw milk with no drug residues (NR)
Study: 24089302
Drug: Intraarticular hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular hyaluronan injection (HS)
Study: 20522296
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced soy/peanut ready-to-use supplementary food (RUSF) at a dosage of 65 kcal/kg/d for up to 8 weeks.
Study: 18622133
Drug: Singing bowl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singing bowl therapy (IG)
Study: 18622133
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (KG)
Study: 15768874
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese herbs
Study: 9190003
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 40 mg of prednisone
Study: 24470281
Drug: EPA-FFA 2
Normalized name: EPA
DrugBank: Icosapent (DB00159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-FFA 2 g daily
Study: 16651509
Drug: Sertraline (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (n = 79)
Study: 14717039
Drug: Brief information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief information and relaxation therapy
Study: 25010430
Drug: Integrated cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive-behavioral therapy (CBT) and voucher-based reinforcement therapy (VBRT)
Study: 25010430
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with attendance-based reward program
Study: 20863381
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in dose of other oral agents (n = 39)
Study: 15965356
Drug: Nicorandil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (15 mg/d)
Study: 1906905
Drug: 0.4 or
Normalized name: 0.4 Orencia 125 MG/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 or 0.8 mg of nitroglycerin
Study: 1906905
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg of cocaine
Study: 6652641
Drug: Symptom duration
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom duration prior to treatment in patients with faster-growing tumors
Study: 6652641
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer control activities to decrease the interval from recognition of symptoms to diagnosis and treatment
Study: 6652641
Drug: Early diagnosis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early diagnosis and treatment during the symptomatic period for patients with faster-growing tumors
Study: 31278224
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin K (n=41)
Study: 29574355
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg/d) plus trifluoperazine (5 mg/d)
Study: 29574355
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/d) alone
Study: 24634003
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Study: 20585005
Drug: Glutamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.25 g/kg/dose)
Study: 3903785
Drug: Triletide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triletide (1.5 g/day)
Study: 3903785
Drug: Carbenoxolone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (0.3 g/day)
Study: 27856714
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 15 l/min
Study: 31254849
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 30 l/min
Study: 27856714
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 45 l/min
Study: 23460810
Drug: Xiaoke Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoke Pill
Study: 11990832
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) therapy
Study: 2527531
Drug: Cilazapril (oral)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (oral)
Study: 2527531
Drug: Cilazaprilat (oral)
Normalized name: cilazapril
DrugBank: Cilazaprilat (DB15565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazaprilat (oral)